Literature DB >> 11587867

Fatal myeloencephalopathy due to accidental intrathecal vincristin administration: a report of two cases.

R Dettmeyer1, F Driever, A Becker, O D Wiestler, B Madea.   

Abstract

We report on two fatal cases of accidental intrathecal vincristine instillation in a 5-year old girl with recurrent acute lymphoblastic leucemia and a 57-year old man with lymphoblastic lymphoma. The girl died seven days, the man four weeks after intrathecal injection of vincristine. Clinically, the onset was characterized by the signs of opistothonus, sensory and motor dysfunction and ascending paralysis. Histological and immunohistochemical investigations (HE-LFB, CD-68, Neurofilament) revealed degeneration of myelin and axons as well as pseudocystic transformation in areas exposed to vincristine, accompanied by secondary changes with numerous prominent macrophages. The clinical course and histopathological results of the two cases are presented. A review of all reported cases in the literature is given. A better controlled regimen for administering vincristine and intrathecal chemotherapy is recommended.

Entities:  

Mesh:

Substances:

Year:  2001        PMID: 11587867     DOI: 10.1016/s0379-0738(01)00394-2

Source DB:  PubMed          Journal:  Forensic Sci Int        ISSN: 0379-0738            Impact factor:   2.395


  2 in total

1.  Chemotherapeutic errors in hospitalised cancer patients: attributable damage and extra costs.

Authors:  Florence Ranchon; Gilles Salles; Hans-Martin Späth; Vérane Schwiertz; Nicolas Vantard; Stéphanie Parat; Florence Broussais; Benoît You; Sophie Tartas; Pierre Jean Souquet; Claude Dussart; Claire Falandry; Emilie Henin; Gilles Freyer; Catherine Rioufol
Journal:  BMC Cancer       Date:  2011-11-08       Impact factor: 4.430

Review 2.  Neuraxial and peripheral misconnection events leading to wrong-route medication errors: a comprehensive literature review.

Authors:  Eugene R Viscusi; Vincent Hugo; Klaus Hoerauf; Frederick S Southwick
Journal:  Reg Anesth Pain Med       Date:  2020-11-03       Impact factor: 6.288

  2 in total

北京卡尤迪生物科技股份有限公司 © 2022-2023.